149 related articles for article (PubMed ID: 10699717)
41. Albumin removal from human serum using surface nanopockets on silica-coated magnetic nanoparticles.
Bhakta S; Dixit CK; Bist I; Macharia J; Shen M; Kadimisetty K; He J; Dutta B; Suib SL; Rusling JF
Chem Commun (Camb); 2017 Aug; 53(66):9254-9257. PubMed ID: 28770934
[TBL] [Abstract][Full Text] [Related]
42. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting.
Li FQ; Su H; Wang J; Liu JY; Zhu QG; Fei YB; Pan YH; Hu JH
Int J Pharm; 2008 Feb; 349(1-2):274-82. PubMed ID: 17870261
[TBL] [Abstract][Full Text] [Related]
43. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity.
Ghosh P; Singha Roy A; Chaudhury S; Jana SK; Chaudhury K; Dasgupta S
Int J Biol Macromol; 2016 May; 86():408-17. PubMed ID: 26820351
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and characterization of TiO(2) nanoparticles: applications in research on the interaction of colloidal TiO(2) with human serum albumin by fluorescence spectroscopy.
Sun T; Liu L; Sun Y; Tan C; Yao F; Liang X; Wang Y; Yang Y; Hu X; Fan J
Anal Sci; 2012; 28(5):491-6. PubMed ID: 22687929
[TBL] [Abstract][Full Text] [Related]
45. Optimisation of one-step desolvation and scale-up of gelatine nanoparticle production.
Geh KJ; Hubert M; Winter G
J Microencapsul; 2016 Nov; 33(7):595-604. PubMed ID: 27556342
[TBL] [Abstract][Full Text] [Related]
46. Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Lee HJ; Park HH; Kim JA; Park JH; Ryu J; Choi J; Lee J; Rhee WJ; Park TH
Biomaterials; 2014 Feb; 35(5):1696-704. PubMed ID: 24262100
[TBL] [Abstract][Full Text] [Related]
47. Effects of Desolvating Agent Types, Ratios, and Temperature on Size and Nanostructure of Nanoparticles from α-Lactalbumin and Ovalbumin.
Etorki AM; Gao M; Sadeghi R; Maldonado-Mejia LF; Kokini JL
J Food Sci; 2016 Oct; 81(10):E2511-E2520. PubMed ID: 27636231
[TBL] [Abstract][Full Text] [Related]
48. Stability study of human serum albumin pharmaceutical preparations.
Oliva A; Santoveña A; Llabres M; Fariña JB
J Pharm Pharmacol; 1999 Apr; 51(4):385-92. PubMed ID: 10385209
[TBL] [Abstract][Full Text] [Related]
49. Preparation of surface-modified albumin nanospheres.
Lin W; Garnett MC; Davies MC; Bignotti F; Ferruti P; Davis SS; Illum L
Biomaterials; 1997 Apr; 18(7):559-65. PubMed ID: 9105596
[TBL] [Abstract][Full Text] [Related]
50. Adsorption of obidoxime onto human serum albumin nanoparticles: drug loading, particle size and drug release.
Kufleitner J; Wagner S; Worek F; von Briesen H; Kreuter J
J Microencapsul; 2010; 27(6):506-13. PubMed ID: 20214419
[TBL] [Abstract][Full Text] [Related]
51. Physicochemical characterization of the freezing behavior of mannitol-human serum albumin formulations.
Hawe A; Friess W
AAPS PharmSciTech; 2006; 7(4):94. PubMed ID: 17285745
[TBL] [Abstract][Full Text] [Related]
52. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
53. Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology.
Li L; Zhao X; Yang C; Hu H; Qiao M; Chen D
Drug Dev Ind Pharm; 2011 Oct; 37(10):1170-80. PubMed ID: 21449822
[TBL] [Abstract][Full Text] [Related]
54. Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process.
Verrecchia T; Huve P; Bazile D; Veillard M; Spenlehauer G; Couvreur P
J Biomed Mater Res; 1993 Aug; 27(8):1019-28. PubMed ID: 8408114
[TBL] [Abstract][Full Text] [Related]
55. Green synthesis of biogenic silver nanoparticles using Solanum tuberosum extract and their interaction with human serum albumin: Evidence of "corona" formation through a multi-spectroscopic and molecular docking analysis.
Ali MS; Altaf M; Al-Lohedan HA
J Photochem Photobiol B; 2017 Aug; 173():108-119. PubMed ID: 28570906
[TBL] [Abstract][Full Text] [Related]
56. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
[TBL] [Abstract][Full Text] [Related]
57. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi HG; Park ES; Youn YS
Int J Pharm; 2016 Jan; 497(1-2):268-76. PubMed ID: 26657273
[TBL] [Abstract][Full Text] [Related]
58. Properties of glutaraldehyde cross-linked vicilin nano- and microparticles.
Ezpeleta I; Irache JM; Gueguen J; Orecchioni AM
J Microencapsul; 1997; 14(5):557-65. PubMed ID: 9292432
[TBL] [Abstract][Full Text] [Related]
59. Formulation of an intermediate product from human serum albumin for the production of a solid dosage form.
Kristó K; Bajdik J; Eros I; Dékány I; Pallai Z; Pintye-Hódi K
Eur J Pharm Biopharm; 2008 Mar; 68(3):741-6. PubMed ID: 17870448
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
